{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:13:21Z","timestamp":1787004801491,"version":"build-2736575974"},"reference-count":87,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1053\/j.gastro.2012.02.012","type":"journal-article","created":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T04:10:05Z","timestamp":1335240605000},"page":"1324-1334.e3","source":"Crossref","is-referenced-by-count":66,"title":["Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals"],"prefix":"10.1053","volume":"142","author":[{"given":"Susanna","family":"Naggie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Sulkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1053\/j.gastro.2012.02.012_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2012.02.012_bib2","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/339042","article-title":"Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group","volume":"34","author":"Sherman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.012_bib3","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the HIV: the D:A:D study","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.gastro.2012.02.012_bib4","doi-asserted-by":"crossref","first-page":"790","DOI":"10.18553\/jmcp.2007.13.9.790","article-title":"Medical costs and resource utilization for hemophilia patients with and without HIV and HCV infection","volume":"13","author":"Tencer","year":"2007","journal-title":"J Manage Care Pharm"},{"key":"10.1053\/j.gastro.2012.02.012_bib5","unstructured":"Naggie S, Park L, Gellad Z, et al. Healthcare utilization and mortality associated with chronic HIV and HCV: more to the story than chronic infection. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27 to March 2, 2011; Boston, MA. Abstract 915."},{"key":"10.1053\/j.gastro.2012.02.012_bib6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2012.02.012_bib7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2012.02.012_bib8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"Mehta","year":"2008","journal-title":"J Community Health"},{"key":"10.1053\/j.gastro.2012.02.012_bib11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jama.297.7.724","article-title":"Molecular diagnostics of hepatitis C virus infection: a systematic review","volume":"297","author":"Scott","year":"2007","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2012.02.012_bib12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2012.02.012_bib13","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jhep.2005.11.009","article-title":"Natural history and predictors of disease severity in chronic hepatitis C","volume":"44","author":"Massard","year":"2006","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2012.02.012_bib14","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(97)05413-5","article-title":"Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C","volume":"350","author":"Darby","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2012.02.012_bib15","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","article-title":"Influence of HIV infection on the course of hepatitis C virus infection: a meta-analysis","volume":"33","author":"Graham","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.012_bib16","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(10)62001-6","article-title":"Increasing burden of liver disease in patients with HIV infection","volume":"377","author":"Joshi","year":"2011","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2012.02.012_bib17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/j.gastro.2008.01.005","article-title":"HIV increases HCV replication in a TGF-beta1-dependent manner","volume":"134","author":"Lin","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.012_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.gastro.2008.03.022","article-title":"Human immunodeficiency virus-related microbial translocation and progression of hepatitis C","volume":"135","author":"Balagopal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.012_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","article-title":"Human Immunodeficiency virus infection modifies the natural history of chronic parenterraly-acquired hepatitis C with an unusually rapid progression to cirrhosis","volume":"26","author":"Soto","year":"1997","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2012.02.012_bib20","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1097\/QAI.0b013e31818651e6","article-title":"Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options","volume":"49","author":"Tebas","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.gastro.2012.02.012_bib21","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S1665-2681(19)31519-4","article-title":"Alcohol use among patients with HIV infection","volume":"10","author":"Bonacini","year":"2011","journal-title":"Ann Hepatol"},{"key":"10.1053\/j.gastro.2012.02.012_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1468-1293.2008.00662.x","article-title":"Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort","volume":"10","author":"Chaudhry","year":"2009","journal-title":"HIV Med"},{"key":"10.1053\/j.gastro.2012.02.012_bib23","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","article-title":"Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection","volume":"362","author":"Qurishi","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2012.02.012_bib24","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.21757","article-title":"Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy","volume":"46","author":"Pineda","year":"2007","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.012_bib25","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","article-title":"Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis","volume":"22","author":"Thein","year":"2008","journal-title":"AIDS"},{"key":"10.1053\/j.gastro.2012.02.012_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(00)02435-1","article-title":"Detection of hepatitis C virus in the semen of infected men","volume":"356","author":"Leruez-Ville","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2012.02.012_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0163-4453(99)90038-5","article-title":"Evidence of hepatitis C virus in cervical smears","volume":"38","author":"Manavir","year":"1999","journal-title":"J Infect"},{"key":"10.1053\/j.gastro.2012.02.012_bib29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1572-0241.2004.04150.x","article-title":"Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study","volume":"99","author":"Vandelli","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2012.02.012_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/sti.79.2.160","article-title":"Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples","volume":"79","author":"Marincovich","year":"2003","journal-title":"Sex Transm Infect"},{"key":"10.1053\/j.gastro.2012.02.012_bib31","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2105\/AJPH.2003.020388","article-title":"Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men","volume":"95","author":"Alary","year":"2005","journal-title":"Am J Public Health"},{"key":"10.1053\/j.gastro.2012.02.012_bib32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1096-9071(199706)52:2<164::AID-JMV8>3.0.CO;2-1","article-title":"Importance of sexual transmission of hepatitis C virus in seropositive pregnant women: a case-control study","volume":"52","author":"Salleras","year":"1997","journal-title":"J Med Virol"},{"key":"10.1053\/j.gastro.2012.02.012_bib33","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00007435-200007000-00007","article-title":"Heterosexual transmission of hepatitis C, hepatitis B, and HIV-1 in a sample of inner-city women","volume":"27","author":"Feldman","year":"2000","journal-title":"Sex Transm Dis"},{"key":"10.1053\/j.gastro.2012.02.012_bib34","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/infdis\/171.4.768","article-title":"Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore-an analysis of 309 sex partnerships","volume":"171","author":"Thomas","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.012_bib35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00007435-199811000-00006","article-title":"Hepatitis C virus infection in Chicago women with or at risk for HIV infection: evidence for sexual transmission","volume":"25","author":"Hershow","year":"1998","journal-title":"Sex Transm Dis"},{"key":"10.1053\/j.gastro.2012.02.012_bib36","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1089\/apc.2009.0111","article-title":"Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS)","volume":"23","author":"Frederick","year":"2009","journal-title":"AIDS Patient Care STDS"},{"key":"10.1053\/j.gastro.2012.02.012_bib37","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1053\/j.gastro.2009.02.006","article-title":"Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men","volume":"136","author":"Van de Laar","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.012_bib38","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/QAD.0b013e3283471cce","article-title":"The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007","volume":"25","author":"Van der helm","year":"2011","journal-title":"AIDS"},{"key":"10.1053\/j.gastro.2012.02.012_bib39","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e32832e5631","article-title":"Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic","volume":"23","author":"Urbanus","year":"2009","journal-title":"AIDS"},{"key":"10.1053\/j.gastro.2012.02.012_bib40","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/QAD.0b013e3281053a0c","article-title":"Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours","volume":"21","author":"Danta","year":"2007","journal-title":"AIDS"},{"key":"10.1053\/j.gastro.2012.02.012_bib41","first-page":"945","article-title":"Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men \u2013 New York City, 2005-1010","volume":"60","author":"Fierer","year":"2011","journal-title":"MMWR"},{"key":"10.1053\/j.gastro.2012.02.012_bib42","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.23808","article-title":"Is sexual contact a major mode of hepatitis C virus transmission?","volume":"52","author":"Tohme","year":"2010","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.012_bib43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/apc.2011.0106","article-title":"Acute hepatitis C virus in an HIV clinic: a screening strategy, risk factors, and perception of risk","volume":"25","author":"Taylor","year":"2011","journal-title":"AIDS Patient Care STDS"},{"key":"10.1053\/j.gastro.2012.02.012_bib44","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/hep.510280330","article-title":"Impact of alcohol on the histological and clinical progression of hepatitis C infection","volume":"28","author":"Wiley","year":"1998","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.012_bib45","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1086\/651422","article-title":"Serologic response to hepatitis B vaccination in HIV-infected patients with isolated positivity for antibodies to hepatitis B core antigen","volume":"50","author":"Chakvetadze","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.012_bib46","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jama.2011.351","article-title":"Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial","volume":"305","author":"Launay","year":"2011","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2012.02.012_bib47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1086\/589722","article-title":"Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine","volume":"198","author":"Cardell","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.012_bib48","doi-asserted-by":"crossref","first-page":"12671","DOI":"10.1073\/pnas.231140698","article-title":"Mechanism of indinavir-induced hyperbilirubinemia","volume":"98","author":"Zucker","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2012.02.012_bib49","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-96-6-714","article-title":"Autoimmune thrombocytopenic purpura in homosexual men","volume":"96","author":"Morris","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2012.02.012_bib50","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/QAI.0b013e3181b79aff","article-title":"Risk factors for thrombocytopenia in HIV-infected patients in the era of potent antiretroviral therapy","volume":"52","author":"Marks","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1053\/j.gastro.2012.02.012_fr51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/j.gastro.2009.09.053","article-title":"MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates","volume":"138","author":"Subramanian","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2012.02.012_fr52","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV co-infection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.012_fr53","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00002030-200303280-00010","article-title":"Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients","volume":"17","author":"Myers","year":"2003","journal-title":"AIDS"},{"key":"10.1053\/j.gastro.2012.02.012_fr54","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2005.02.025","article-title":"Prediction of hepatic fibrosis in HIV\/HCV co-infected patients using serum fibrosis markers: the SHASTA index","volume":"43","author":"Kelleher","year":"2005","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2012.02.012_fr55","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/597350","article-title":"Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection","volume":"48","author":"Kirk","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.012_fr56","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2012.02.012_fr57","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus Infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2012.02.012_fr58","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.23020","article-title":"Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus","volume":"50","author":"Berenguer","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.012_fr59","unstructured":"Sulkowski M, Mehta S, Sutcliffe C, et al. Baseline liver disease is independently associated with risk of death among 631 HIV\/HCV co-infected adults with histologic staging. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16\u201319, 2010; San Francisco, CA. Abstract 166."},{"key":"10.1053\/j.gastro.2012.02.012_fr60","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2012.02.012_fr61","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2012.02.012_fr62","unstructured":"Rodriguez-Torres M, Slim J, Bhatti L, et al. Standard versus high dose ribavirin in combination with peginterferon alfa-2a (40KD) in genotype 1 (G1) HCV patients coinfected with HIV: final results of the PARADIGM Study. Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases; October 30 to November 3, 2009; Boston, MA. Abstract 1561."},{"key":"10.1053\/j.gastro.2012.02.012_fr63","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard inteferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2012.02.012_fr64","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/aid.2007.0011","article-title":"Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO Trial","volume":"23","author":"Nunez","year":"2007","journal-title":"AIDS Res Human Retrovirus"},{"key":"10.1053\/j.gastro.2012.02.012_fr65","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"key":"10.1053\/j.gastro.2012.02.012_fr66","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hep.22598","article-title":"Randomized trial comparing pegylated interferon alfa-2b versus pegylated interferon alfa-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients","volume":"49","author":"Laguno","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2012.02.012_fr67","doi-asserted-by":"crossref","first-page":"F23","DOI":"10.1097\/QAD.0b013e3283391d6d","article-title":"Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV\/hepatic C virus-coinfected patients","volume":"24","author":"Rallon","year":"2010","journal-title":"AIDS"},{"key":"10.1053\/j.gastro.2012.02.012_fr68","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/QAD.0b013e32801086da","article-title":"Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic","volume":"20","author":"Mehta","year":"2006","journal-title":"AIDS"},{"key":"10.1053\/j.gastro.2012.02.012_fr69","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2012.02.012_fr70","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2012.02.012_fr71","doi-asserted-by":"crossref","unstructured":"Bruno S, Vierling JM, Esteban R, et al. Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype-1 with advanced fibrosis\/cirrhosis: subgroup analysis of SPRINT-2 and RESPOND-2 studies. Presented at: 46th Annual Meeting of the European Association for the Study of Liver Diseases; March 30 to April 3, 2011; Berlin, Germany. Abstract 7.","DOI":"10.1016\/S0168-8278(11)60009-3"},{"key":"10.1053\/j.gastro.2012.02.012_fr72","doi-asserted-by":"crossref","unstructured":"Poordad F, Bronowicki JP, Gordon SC, et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir combination therapy. Presented at: 46th Annual Meeting of the European Association for the Study of Liver Diseases; March 30 to April 3, 2011; Berlin, Germany. Abstract 12.","DOI":"10.1016\/S0168-8278(11)60014-7"},{"key":"10.1053\/j.gastro.2012.02.012_fr73","unstructured":"Marcellin P, Jacobson IM, Zeuzem S, et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin: analysis of predefined subpopulations in the phase 3 ADVANCE trial. Presented at: 46th Annual Meeting of the European Association for the Study of Liver Diseases; March 30 to April 3, 2011; Berlin, Germany. Abstract 451."},{"key":"10.1053\/j.gastro.2012.02.012_fr74","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Andreone P, Pol S, et al. REALIZE trial final results: telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon\/ribavirin. Presented at: 46th Annual Meeting of the European Association for the Study of Liver Diseases; March 30 to April 3, 2011; Berlin, Germany. Abstract 5.","DOI":"10.1016\/S0168-8278(11)60007-X"},{"key":"10.1053\/j.gastro.2012.02.012_fr75","unstructured":"Dieterich DT, Soriano V, Sherman KE, et al. Telaprevir in combination with peginterferon alfa-2a\/ribavirin in HCV\/HIV co-infected patients: SVR12 interim analysis. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5\u20138, 2011; Seattle, WA. Abstract 46."},{"key":"10.1053\/j.gastro.2012.02.012_fr76","unstructured":"Sulkowski M, Pol S, Cooper C, et al. Boceprevir plus peginterferon\/ribavirin for the treatment of HCV\/HIV co-infected patients. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5\u20138, 2011; Seattle, WA. Abstract 47."},{"key":"10.1053\/j.gastro.2012.02.012_fr77","unstructured":"Van Heeswijk R, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27 to March 2, 2011; Boston, MA. Abstract 119."},{"key":"10.1053\/j.gastro.2012.02.012_fr78","unstructured":"Van Heeswijk R, Gard V, Boogaerts, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17\u201320, 2011; Chicago, IL. Abstract A1-1738a."},{"key":"10.1053\/j.gastro.2012.02.012_fr79","unstructured":"Kasserra C, Hughes E, Treitel M, et al. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27 to March 2, 2011; Boston, MA. Abstract 118."},{"key":"10.1053\/j.gastro.2012.02.012_fr80","doi-asserted-by":"crossref","unstructured":"Hulskotte E, Feng HP, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5\u20138, 2011; Seattle, WA. Abstract 771LB.","DOI":"10.1093\/cid\/cis968"},{"key":"10.1053\/j.gastro.2012.02.012_fr81","unstructured":"de Kanter CTMM, Blonk MI, Colbers APH, et al. Pharmacokinetic of the HIV integrase inhibitor raltegravir. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5\u20138, 2011; Seattle, WA. Abstract 772LB."},{"key":"10.1053\/j.gastro.2012.02.012_fr82","article-title":"Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons","author":"Thomas","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.012_fr83","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1016\/j.jhep.2005.11.028","article-title":"Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)?","volume":"44","author":"Miro","year":"2006","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2012.02.012_fr84","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1086\/379254","article-title":"Survival of human immunodeficiency virus-infected liver transplant recipients","volume":"188","author":"Ragni","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1053\/j.gastro.2012.02.012_fr85","unstructured":"Terrault NA, Barin B, Schiano T, et al. Survival and risk of severe HCV recurrence in liver transplant recipients co-infected with HIV and HCV. Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases; October 30 to November 1, 2009; Boston, MA. Abstract 195."},{"key":"10.1053\/j.gastro.2012.02.012_fr86","doi-asserted-by":"crossref","unstructured":"Soriano V, Sherman KE, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. AIDS 201;25:2197\u20132208.","DOI":"10.1097\/QAD.0b013e32834bbb90"},{"key":"10.1053\/j.gastro.2012.02.012_fr87","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/474S5a","article-title":"New drugs hit the target","volume":"474","author":"Schlutter","year":"2011","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2012.02.012_fr88","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomized, double-blind, placebo-controlled, dose-escalation trial","volume":"376","author":"Gane","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2012.02.012_fr89","unstructured":"Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN\/RBV for up to 28 days in treatment na\u00efve, genotype 1 HCV subjects. Presented at: 61st Annual Meeting of the American Association for the Study of Liver Diseases; October 29 to November 2, 2010; Boston, MA. Abstract LB-1."},{"key":"10.1053\/j.gastro.2012.02.012_fr90","doi-asserted-by":"crossref","unstructured":"Lok A, Gardiner D, Lawitz E, et al. Quadruple therapy with BMS-790052, BMS-650032 and peg-IFN\/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. Presented at: 46th Annual Meeting of the European Association for the Study of Liver Diseases; March 30 to April 3, 2011; Berlin, Germany. Abstract 418.","DOI":"10.1016\/S0168-8278(11)61358-5"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508512002247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508512002247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T17:03:34Z","timestamp":1642093414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508512002247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":87,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0016508512002247"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2012.02.012","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718020309.793478810","asserted-by":"object"}]},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}